Key Developments: Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

4,214JPY
11 Jul 2014
Price Change (% chg)

¥19 (+0.45%)
Prev Close
¥4,195
Open
¥4,141
Day's High
¥4,235
Day's Low
¥4,139
Volume
1,406,900
Avg. Vol
1,030,719
52-wk High
¥4,440
52-wk Low
¥3,694

Search Stocks

Latest Key Developments (Source: Significant Developments)

NanoCarrier Co Ltd announces exclusive license agreement with Eisai Co., Ltd
Monday, 23 Jun 2014 02:00am EDT 

NanoCarrier Co Ltd:Reached a world-wide, exclusive license agreement, which allows NanoCarrier to obtain rights to develop, sell and market an active compound called E7974 for new drug development, which is owned and has been being developed by Eisai with Eisai.NanoCarrier will start research and development activities, including clinical trials, in order to develop micelle-based drugs encapsulating E7974 as an active compound.  Full Article

Eisai Co Ltd's Eisai Inc announces phase III trial with Antiepileptic Drug Perampanel meets primary endpoint
Monday, 16 Jun 2014 10:05pm EDT 

Eisai Inc:Says a phase III clinical trial (study 332) of its in-house-discovered AMPA receptor antagonist perampanel has met its primary endpoint in patients with primary generalized tonic-clonic (PGTC) seizures, a severe form of seizures.An analysis of the trial data demonstrates that perampanel met its primary efficacy endpoint (reduction in seizure frequency per 28 days).The most frequently reported adverse events in this trial (>10 pct in the perampanel arm and greater than placebo) were dizziness, fatigue, headache, irritability and somnolence.Eisai Inc is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd.  Full Article

Eisai announces application of IFRS
Tuesday, 25 Mar 2014 02:30am EDT 

Eisai Co Ltd:To apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan Accounting Standards, starting from the financial report for first quarter of fiscal year ending March 2015.  Full Article

Eisai Co Ltd collaborates with Liverpool School of Tropical Medicine And University of Liverpool
Thursday, 20 Mar 2014 09:50am EDT 

Eisai Co Ltd:Enters collaboration with Liverpool School of Tropical Medicine and University of Liverpool to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of filariasis.  Full Article

Eisai Co Ltd and Biogen Idec enter collaboration to develop and commercialize alzheimer's disease treatments
Wednesday, 5 Mar 2014 02:00am EST 

Eisai Co Ltd:Eisai Co Ltd and Biogen Idec entered into collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.Agreement also provides Eisai with option to jointly develop and commercialize two of Biogen Idec's candidates for AD, anti-amyloid beta (Aβ) antibody BIIB037 and anti-tau monoclonal antibody.Both companies will share overall costs, including research and development expenses, with Eisai booking all sales for E2609 and BAN2401 and with profits to be split between the companies.Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments.  Full Article

Eisai Co Ltd announces initiation of phase 3 trial of Eribulin Mesylate Injection Versus Weekly Paclitaxel in first and second lines of metastatic breast cancer
Thursday, 27 Feb 2014 08:15am EST 

Eisai Co Ltd:Start of randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second line treatment for HER2-negative locally recurrent or metastatic breast cancer (MBC).Recruitment is active for this multicenter study, conducted in partnership with the Academic and Community Cancer Research United (ACCRU) group.Aims to enroll about 910 patients across the U.S. the primary endpoint is overall survival.Research study involves an investigational use of eribulin mesylate.Efficacy and safety of eribulin mesylate in first- and second-line MBC have not been established and this release is not intended to convey conclusions of efficacy and safety.  Full Article

Eisai Co Ltd Phase III trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of redioiodine-refractory differentiated thyroid cancer
Sunday, 2 Feb 2014 10:30pm EST 

Eisai Co Ltd:Says the Phase III SELECT trial of lenvatinib, an investigational selective tyrosine kinase inhibitor with a novel binding mode, the first-in-class of its kind, met its primary endpoint.Says compared to placebo, lenvatinib showed a statistically improvement in progression free survival in patients with radioiodine-refractory differentiated thyroid cancer.  Full Article

Eisai Co Ltd announces result of early-retirement program
Sunday, 2 Feb 2014 10:30pm EST 

Eisai Co Ltd:Says 396 employees have taken up the offer of the early-retirement program announced on Nov. 29, 2013.Says effective date of retirement is Mar. 31.Says a premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

European Commission grants orphan drug status to Eisai Co Ltd's amatuximab for treatment of malignant mesothelioma
Tuesday, 21 Jan 2014 07:01pm EST 

Eisai Co Ltd:Says the investigational monoclonal antibody amatuximab (development code: MORAb-009), has been granted orphan drug designation (ODD) for the treatment of malignant mesothelioma by the European Commission.Says Malignant mesothelioma is a rare form of cancer that affects an estimated in 50,000 (0.2/10,000) people per year in Europe.Says studies have shown highest incidence in the UK and Ireland and lowest in Eastern Europe.Says this aggressive form of lung cancer is caused by asbestos exposure and despite a dramatic decrease in asbestos use since the mid-70s its incidence is expected to increase.Says amatuximab has high affinity and specificity for mesothelin, a protein which is overexpressed in people with malignant mesothelioma.Says amatuximab was discovered and developed through Morphotek, a subsidiary wholly owned by Eisai.  Full Article

Eisai Co Ltd announces new partnership with Esteve to promote anti-epilepsy drug Zonegran (Zonisamide) in Spain
Monday, 9 Dec 2013 07:02pm EST 

Eisai Co Ltd:Says that it has selected Esteve, a Spanish pharmaceutical company with a comprehensive neurology franchise, to become its epilepsy partner in Spain to promote Zonegran (zonisamide).Says Zonisamide, an anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AED, is indicated as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;.Says and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents and children aged six years and above.  Full Article

REFILE-TABLE-Eisai -2013/14 group results

(Adds company forecast) May 13 - Eisai Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Mar 31, 2014 Mar 31, 2013 Mar 31, 2015 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST (Based on JPS)(Based on JPS)(Based on

Search Stocks